[11]
Dumic-Cule I, Ivanac G, Lucijanic T, et al. Drug-induced bone loss: a major safety concern in Europe. Expert opinion on drug safety 2018; 17(10): 1005-4.
[20]
Bayani MA, Karkhah A, Hoseini SR, Qarouei R, Nourodini HQ, Bijani A, et al. The relationship between type 2 diabetes mellitus and osteoporosis in elderly people: a cross-sectional study. International Biological and Biomedical Journal 2016; 2(1): 39-46.
[23]
Hamilton EJ, Davis WA, Bruce DG, Davis TM. Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study diabetes research and clinical practice 2017; 134: 153-60.
[44]
Zhang C, Li L, Zhao B, Jiao A, Li X, Sun N, et al. Ghrelin protects against dexamethasone-induced INS-1 cell apoptosis via ERK and p38MAPK signaling. International journal of endocrinology 2016 2016.
[75]
Baran D, Ashkar J, Galin I, Sandler D, Segura L, Courtney M, Eds. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. Transplantation proceedings. 2002.
[83]
Martin-Fernandez M, Rubert M, Montero M, de la Piedra C, Eds. Effects of cyclosporine, tacrolimus, and rapamycin on osteoblasts Transplantation proceedings. Elsevier 2017.
[84]
Smallwood G, Burns D, Fasola C, Steiber A, Heffron T, Eds. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic Transplantation proceedings. Elsevier 2005.
[92]
Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, et al. Prevention of the Glucose Intolerance of Thiazide Diuretics by Maintenance of Body-Potassium Diuretika III. Springer 1986; pp. 98-109.
[117]
Nehra AK, Alexander JA, Loftus CG, Nehra V, Eds. Proton pump inhibitors: review of emerging concerns Mayo Clinic Proceedings. Elsevier 2018.
[119]
De Vito P, Candelotti E, G, Ahmed R, Luly P, J, Davis P, Incerpi S, et al. Role of thyroid hormones in insulin resistance and diabetes. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents) 2015; 15(1): 86-93.
[122]
Pasupathi P, Bakthavathsalam G, Saravanan G, Sundaramoorthi R. Screening for thyroid dysfunction in the diabetic/non-diabetic population. Thyroid Science 2008; 3(8): 1-6.
[132]
Chandankhede M, Gupta M, Chari S. Correlation Between Insulin Resistance and Homocysteine in Hypothyroid Patients. Journal of Krishna Institute of Medical Sciences 2018; 7(1) [JKIMSU]
[135]
Prasad RS, Nandkeoliar MK, Rai G, Srivastava S, Saxena R. Assessment of insulin resistance in diabetic hypothyroidism patients–A clinical insight. population 2017; 3-4.
[145]
Barbosa A, Mascarenhas M, Bicho M, Oliveira AG. Trabecular Bone Score and Vertebral Fracture Assessment in Portuguese Premenopausal Women with Hyperthyroidism Available at SSRN 3204911 2018
[180]
Ngarmukos C. Chailurkit Lo, Chanprasertyothin S, Hengprasith B, Sritara P, Ongphiphadhanakul B. A reduced serum level of total osteocalcin in men predicts the development of diabetes in a long‐term follow‐up cohort. Horumon To Rinsho 2012; 77(1): 42-6.
[193]
Xia J, Zhong Y, Huang G, Chen Y, Shi H, Zhang Z, Eds. The relationship between insulin resistance and osteoporosis in elderly male type 2 diabetes mellitus and diabetic nephropathy Annales d’endocrinologie. Elsevier 2012.
[216]
Pons-Duran C, Piqueras M, Aponte J, Ter Kuile F. Mefloquine for preventing malaria in pregnant women. Cochrane Database of Syst ematic Reviews 2018; 3p CD011444
[217]
Yadav RK, Rawat JK, Gautam S, et al. Antidiabetic activity of mefloquine via GLP-1 receptor modulation against STZ–NAinduced diabetes in albino wistar rats. 3 Biotech 2018; 8(5): 240.
[227]
Andreassen KV, Michael FM, Hjuler ST, et al. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts anti-obesity and anti-diabetic effects in rats. Am J Physiol Heart Circ Physiol 2014.
[232]
Rosen HN, Rosen C, Schmader K, Mulder J. Calcitonin in the prevention and treatment of osteoporosis 2017.
[235]
Hamdi RA. Evaluation of Serum Osteocalcin level in Iraqi Postmenopausal women with primary osteoporosis. Journal of the Faculty of Medicine 2013; 55(2): 166-9.
[237]
Susanto LTM. Serum osteocalcin and bone mineral density in postmenopausal women. Universa Medicina 2016; 30(3): 155-61.
[243]
García RR, Moreno PR, Muñoz-Torres M. Osteocalcin and atherosclerosis: a complex relationship. Diabetes Res Clin Pract 2011; 92(3): 405-6.
[257]
Karsenty G, Ducy PF. Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass. Google Patents 2017.
[267]
Wang Y, Gao C, Guo T, Yang R, Shao F, Ma W, et al. Association of insulin-like growth factor-I receptor and-II receptor gene polymorphisms with osteoporosis in postmenopausal women of Han Chinese. Int J Clin Exp Pathol 2017; 10(2): 2100-9.
[276]
Gamble J-M, Donnan JR, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: a cohort study diabetes research and clinical practice 2018; 136: 159-67.
[288]
Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazoli dinediones and secondary osteoporosis. Current osteoporos is reports 2010; 8(4): 178-84.